ImmunityBio Inc. experienced a significant share price increase on Tuesday, with stock closing at $9.29, reflecting investor enthusiasm regarding the biotechnology company’s international expansion efforts.
The catalyst for the gains was a meeting between company founder Dr. Patrick Soon-Shiong and Turkish President Recep Tayyip Erdogan. While specific details about the discussion were not released, Soon-Shiong’s public comments suggested the meeting centered on establishing Turkey as a regional hub for cancer treatment. The interaction generated buying pressure among market participants who interpreted it as evidence of progress on the firm’s Turkey entry plans.
ImmunityBio has been pursuing regulatory approvals for Anktiva, an immunotherapy medication developed for non-muscle invasive bladder cancer. The drug has obtained approval in 34 countries across multiple regions including the United States, United Kingdom, Saudi Arabia, Macau, and various European nations. To support its international growth initiatives, the company raised $100 million, comprising $75 million from non-dilutive financing through Oberland Capital and $25 million from a debt-conversion arrangement with Nant Capital LLC.
Financial results demonstrated substantial revenue growth, with second-quarter revenues reaching $51.24 million, a 94 percent increase from $26.4 million in the corresponding prior-year period. However, the company reported a net loss of $230.39 million, representing a 148 percent widening from the prior-year loss of $92.57 million, attributed to increased operational costs.
Institutional interest in the company strengthened during the quarter, with hedge fund positions increasing to 27 from 25 in the prior quarter, while their combined holdings climbed 62.6 percent to $314.9 million from $193.7 million.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI